Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro
Combined Effects of Fe3O4 Nanoparticles and Chemotherapeutic Agents on Prostate Cancer Cells In Vitro
复制标题
DOI：
10.3390/app8010134
复制
发表时间：
2018-01-01
影响因子：
2.7
通讯作者：
Watanabe, Masatoshi
中科院分区：
文献类型：
--
作者：
Kojima, Kanako;Takahashi, Sanai;Watanabe, Masatoshi
转移性去势抵抗前列腺癌(MCRPC)患者预后较差。以多西紫杉醇(DTX)为基础的治疗是目前mCRPC患者的标准治疗。将传统化疗药物与纳米粒子(NPs)，特别是氧化铁纳米粒子相结合，可以克服严重的副作用和耐药性，从而建立新的治疗策略。我们先前报道了Fe3O4纳米颗粒(Fe3O4 NPs)与DTX在体外对前列腺癌细胞的联合作用。在这项研究中，我们研究了Fe3O4纳米颗粒与雷帕霉素或卡铂在体外对前列腺癌细胞的联合作用。Fe3O4纳米粒子处理DU145和PC-3细胞后，细胞内的ROS水平呈浓度依赖性增加。100g/mLFe3O4纳米颗粒作用于两种细胞株72h后，细胞活力受到明显抑制，但抑制效果不同。100 mU g/mLFe3O4纳米颗粒与10 mU M卡铂或10 nM雷帕霉素联合作用于DU145和PC-3细胞后，细胞存活率明显下降。Fe3O4纳米粒与雷帕霉素联合作用于PC-3细胞，与卡铂联合作用于DU145细胞，对细胞的凋亡有协同作用。这些结果表明，纳米Fe3O4和各种化疗药物联合治疗mCRPC是一种新的治疗策略。
Patients with metastatic castration-resistant prostate cancer (mCRPC) have poor outcomes. Docetaxel (DTX)-based therapy is a current standard treatment for patients with mCRPC. Approaches combining conventional chemotherapeutic agents and nanoparticles (NPs), particularly iron oxide NPs, may overcome the serious side effects and drug resistance, resulting in the establishment of new therapeutic strategies. We previously reported the combined effects of Fe3O4 nanoparticles (Fe3O4 NPs) with DTX on prostate cancer cells in vitro. In this study, we investigated the combined effects of Fe3O4 NPs and rapamycin or carboplatin on prostate cancer cells in vitro. Treatment of DU145 and PC-3 cells with Fe3O4 NPs increased intracellular reactive oxygen species (ROS) levels in a concentration-dependent manner. Treatment of both cell lines with 100 g/mL Fe3O4 NPs for 72 h resulted in significant inhibition of cell viability with a different inhibitory effect. Combination treatments with 100 mu g/mL Fe3O4 NPs and 10 mu M carboplatin or 10 nM rapamycin in DU145 and PC-3 cells significantly decreased cell viability. Synergistic effects on apoptosis were observed in PC-3 cells treated with Fe3O4 NPs and rapamycin and in DU145 cells with Fe3O4 NPs and carboplatin. These results suggest the possibility of combination therapy with Fe3O4 NPs and various chemotherapeutic agents as a novel therapeutic strategy for patients with mCRPC.